Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally underscores the company's status as the undisputed titan of the large-cap healthcare sector, a position bolstered by
As the first month of 2026 draws to a close, the narrative that dominated Wall Street for the better part of three years—the undisputed reign of mega-cap technology—is rapidly fracturing. In its place, a massive "sector rotation" is taking hold, fundamentally altering the landscape for institutional and retail
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
Nvidia is a tech stock that has outpaced the broader markets by a significant margin over the past decade. Is NVDA still a good buy as Jensen Huang prepares to visit China?
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY) breached their fiduciary duties to Eli Lilly and its shareholders.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation for its drug, sofetabart mipitecan, intended to treat a specific type of ovarian cancer.
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026, soundly beating Wall Street’s expectations. The healthcare giant accompanied its earnings beat with a bold 2026 financial forecast, projecting
In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the J.P. Morgan Healthcare Conference in January 2026, the five-year partnership represents a massive bet on the convergence of generative AI and life sciences. [...]
Eli Lilly's stock is experiencing short-term volatility due to its proximity to a 52-week high and upcoming earnings, amid strong analyst support and mixed technical indicators.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with Zoetis (NYSE:ZTS).
LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq Stock Market today. The move marks the final countdown for one of the most significant listing migrations in recent history, as
In a move that signals a paradigm shift for the pharmaceutical industry, NVIDIA (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) have announced the launch of a $1 billion joint AI co-innovation lab. Unveiled on January 12, 2026, during the opening of the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, this landmark [...]
